Tyra Biosciences, Inc. Common Stock (TYRA) Stock
NASDAQ · TYRA
21.11
Fundamentals
Market cap
$1.50B
Price / Earnings ratio
-9.0x
Price / Sales ratio
N/A
Price / Book ratio
3.8x
Return on assets
-40.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Investors Business Daily
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
NeutralTYRASeptember 9, 2026
Investors Business DailyNeutral
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
TYRA

Stocktwits
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
NeutralTYRASeptember 4, 2026
StocktwitsNeutral
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
TYRA

The Motley Fool
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
NeutralTYRAMarch 20, 2026
The Motley FoolNeutral
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
TYRA

The Motley Fool
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
NeutralTYRADecember 23, 2025
The Motley FoolNeutral
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
TYRA
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
339M224M112M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-119.9M
Net incomeEarnings
No data available
% positive news of 5 articles
published over the past 14 days
Latest news

Investors Business Daily
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
NeutralTYRASeptember 9, 2026
Investors Business DailyNeutral
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
TYRA

Stocktwits
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
NeutralTYRASeptember 4, 2026
StocktwitsNeutral
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
TYRA

The Motley Fool
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
NeutralTYRAMarch 20, 2026
The Motley FoolNeutral
This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position
TYRA

The Motley Fool
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
NeutralTYRADecember 23, 2025
The Motley FoolNeutral
Tyra Biosciences Director Sells 247,000 Shares for $5 Million After 38% Rally
TYRA

24/7 Wall Street
Post-Election Insider Buying in These 6 Stocks Is Huge
NeutralTYRANovember 17, 2024
24/7 Wall StreetNeutral
Post-Election Insider Buying in These 6 Stocks Is Huge
TYRA
About Tyra Biosciences, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees87
CEODr. Todd Harris Ph.D.
IPO DateSep 13, 2021
HeadquartersCarlsbad, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, CEO, President & Director | 1979 |
| Mr. Bhavesh Ashar M.B.A. | Chief Operating Officer | 1969 |
| Dr. Douglas Warner M.D. | Chief Medical Officer | 1972 |
| Mr. Daniel Bensen | Co-Founder & Chief Discovery Officer | 1975 |
| Mr. Alan Fuhrman CPA | Chief Financial Officer | 1957 |
| Ms. Julia Rueb | VP of Finance & Principal Accounting Officer | 1986 |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer | 1955 |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer | 1963 |
| Mr. Ali D. Fawaz J.D. | General Counsel & Secretary | — |
| Ms. Sarah Honig | Senior VP of Corporate Development & Strategy | — |
Fundamentals
Valuation
Market cap$1.50B
Price-to-sales ratioN/A
Price-to-book value3.78
Price-earnings ratio-9.00
Return on Equity-43.00%
Return on SalesN/A
Return on Assets-40.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.39
Income Statement
Average volume1,251,829
EBITDA$-130.56M
1 year high (52w)$40.65
1 year low (52w)$12.40
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$40.67
Est return
86.89%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.0 | +30.4 | +9.1 | -33.0 | ||||||||
| 2022 | -7.0 | -12.5 | -3.7 | -33.2 | -18.7 | +13.3 | +27.1 | -33.2 | +28.9 | -12.0 | -0.7 | +9.4 |
| 2023 | +50.2 | +0.1 | +25.8 | -11.4 | +2.0 | +23.8 | -3.5 | +5.8 | -8.2 | -11.4 | -1.3 | +19.3 |
| 2024 | -4.6 | +53.7 | -17.7 | +1.3 | -11.3 | -0.9 | +28.2 | +5.8 | +9.7 | -27.0 | -4.3 | -12.4 |
| 2025 | +0.2 | -15.5 | -17.0 | +18.1 | -13.2 | -0.3 | +12.4 | +22.2 | +11.7 | +18.0 | +46.2 | +26.3 |
| 2026 | +15.0 | +7.4 | +17.8 | -9.2 | -1.9 | +5.1 | +8.4 | -21.9 | -14.0 |



